Efforts to redirect the immune system to kill cancer cells have generated extraordinary hope and interest, but face the fundamental problem of how to avoid also killing healthy cells. To overcome this obstacle, the principals of Immunathon have invented a new targeting mechanism, activated by abnormal patterns of gene expression that are hallmarks of cancer. Involved inthe Mass Challenge during 2014, and with close ties ot Harvard and Draper Labs, the principals of the firm indicate intent to partner with biotech and pharmaceutical companies, and generate for them cancer immunotherapy drugs with dramatically improved safety and efficacy.
